<DOC>
	<DOCNO>NCT01458405</DOCNO>
	<brief_summary>The purpose study determine whether Allogeneic Cardiosphere-Derived Cells ( CAP-1002 ) safe effective decrease infarct size patient myocardial infarction .</brief_summary>
	<brief_title>Allogeneic Heart Stem Cells Achieve Myocardial Regeneration</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>Inclusion Criteria 1 . History MI ( STEMI NSTEMI ) within prior 12 month due coronary artery event evidence least two follow : typical ischemic symptom , serial STT change ( new ST elevation new leave bundle block ) and/or elevate troponin CKMB &gt; 5 time upper limit normal . Also least one follow : development pathological Q wave ECG change , image evidence new loss viable myocardium , new regional wall motion abnormality . 2 . History percutaneous coronary intervention ( PCI ) , stent placement result TIMI flow = 3 , coronary artery supplying infarcted , dysfunctional territory treatment infuse . 3 . At least one assessment leave ventricular ejection function ( LVEF ) ≤0.45 determine one standard modality ( echocardiography , ventriculography , nuclear imaging , CT and/or MRI ) prior screen period . For subject fulfill criterion Recent MI ( i.e. , within 90 day MI ) time screen visit : assessment must postreperfusion index MI recent test prior screening period . For subject fulfill criterion Chronic MI ( i.e. , great 90 day MI ) time screen visit : assessment must least 21 day postreperfusion index MI recent test prior screening period . Note : subject may screen Recent MI randomize Chronic MI stratum infusion date &gt; 90 day postMI . 4 . Left ventricular infarct size ≥ 15 % leave ventricular mass qualify infarctrelated region infuse determine centrally read screen MRI , associate thin and/or hypokinesis , akinesis , dyskinesis , large aneurysmal area infarcted region . 5 . No revascularization clinically indicated time subject assess participation clinical trial . 6 . Ability provide inform consent followup protocol procedure . 7 . Age ≥ 18 year . Exclusion Criteria 1 . Subjects history coronary artery bypass surgery , patent graft ( arterial saphenous vein graft ) attach coronary artery infuse . 2 . Diagnosed suspected myocarditis . 3 . History cardiac tumor , cardiac tumor demonstrate screen MRI . 4 . History acute coronary syndrome 4 week prior study infusion . 5 . History previous stem cell therapy . 6 . History radiation treatment central leave side thorax . 7 . Current history ( within previous 5 year ) systematic autoimmune connective tissue disease include , limited , giant cell myocarditis , cardiac systemic sarcoidosis , Dressler 's syndrome , chronic recurrent persistent pericarditis . 8 . History current treatment immunosuppressive , antiinflammatory , agent treat manifestation systemic immunologic reaction , include chronic systemic corticosteroid , biologic agent target immune system , antitumor antineoplastic drug , antiVEGF , chemotherapeutic agent within 3 month prior enrollment . 9 . Prior ICD and/or pacemaker placement study image site train certify specifically protocol conduct cardiac MRI subject ICD and/or pacemaker placement . . Presence pacemaker and/or ICD generator follow limitations/conditions exclude : . Manufactured year 2000 , ii . Leads implant &lt; 6 week prior sign inform consent , iii . Nontransvenous epicardial , abandon , nofixation lead , iv . Subcutaneous ICDs , v. Leadless pacemaker , vi . Any condition , judgement devicetrained staff , would deem MRI contraindicate . b . Pacemaker dependence ICD ( Note : pacemakerdependent candidate without ICD exclude ) . c. A cardiac resynchronization therapy ( CRT ) device implant &lt; 3 month prior sign inform consent . 10 . Estimated glomerular filtration rate &lt; 30 mL/min . 11 . Participation ongoing protocol study experimental drug device , participation interventional clinical trial within last 30 day . 12 . Diagnosis arrhythmogenic right ventricular cardiomyopathy . 13 . Current alcohol drug abuse . 14 . Pregnant/nursing woman woman childbearing potential agree use least two form active highly reliable method ( ) contraception . Acceptable method contraception include contraceptive pill , depoprogesterone injection , barrier contraceptive condom without spermicide cream gel , diaphragms cervical cap without spermicide gel , intrauterine device ( IUD ) . 15 . Human Immunodeficiency Virus ( HIV ) infection . 16 . Viral hepatitis . 17 . Uncontrolled diabetes ( HbA1c &gt; 9 % ) . 18 . Abnormal liver function ( SGPT/ALT &gt; 3 time upper reference range ) and/or abnormal hematology ( hematocrit &lt; 25 % , WBC &lt; 3000 µl , platelets &lt; 100,000 µl ) study without reversible , identifiable cause . 19 . Sustained ventricular tachycardia ( VT ) nonsustained ventricular tachycardia &gt; 30 beat , associate acute phase previous MI ( &gt; 48 hour MI onset ) new acute ischemic episode . 20 . Ventricular fibrillation associate new acute ischemic episode . 21 . New York Heart Association ( NYHA ) Class IV congestive heart failure . 22 . Evidence tumor screen chest/abdominal/pelvic ( body ) CT scan . 23 . Any prior transplant . 24 . Known hypersensitivity dimethyl sulfoxide ( DMSO ) . 25 . Known hypersensitivity bovine product . 26 . Any malignancy within 5 year ( except insitu nonmelanoma skin cancer insitu cervical cancer ) sign ICF . 27 . Any condition reason , opinion Investigator Medical Monitor , would render subject unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Heart Attack</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Left ventricular dysfunction</keyword>
	<keyword>Congestive heart failure</keyword>
</DOC>